Andrea is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group.Her practice includes advising national and international pharmaceutical and biotech companies, medical product manufacturers and food product producers on intellectual property law and regulatory issues. A focus of her practice is advising on complex, often cross-border, projects, in particular research and development cooperations, manufacturing and distribution agreements and licences, as well as advice on transactions.
|Since 2020||Salary Partner, Taylor Wessing|
|2015 – 2019||Senior Associate, Taylor Wessing|
|Since 2012||Lecturer for presentation methods, University of Mannheim|
|2010 – 2012||Research and teaching Assistant, Institute for Medical Law of the Universities of Heidelberg and Mannheim (IMGB)|
|2018||Ph.D. in law, University of Mannheim|
|2015||Admitted as a lawyer, Munich|
|2015||Second state examination, Wiesbaden|
|2013 – 2015||Legal clerkship including stages at an international law firm in Frankfurt; the legal department of a healthcare corporation in Bad Homburg v.d.H and the German Desk of a Korean law firm in Seoul|
|2012||Additional qualification in pharmaceutical law, University in Marburg|
|2010||First state examination|
|2005 – 2010||Legal studies, University of Mannheim|
With a new legal framework, the EU is trying to catch up with the state of development of new genomic techniques. At present, they are subject to the rigid regulatory regime of Genetic Engineering Law, and haste is called for.
1 / 4 观点
Taylor Wessing advises Hauck & Aufhäuser and mBank on voluntary public exchange offer of Vita 34 AG to the shareholders of Polish PBKM